Fig. 1
From: In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis
a Hyponatraemia Pathway S/Osmol, Serum Osmolality(mOsmol/kg); U/Osmol, Urine Osmolality(mOsmol/kg); Na+, Sodium (mmol/L); SIADH, Syndrome of Inappropriate ADH; GCS, Glasgow Coma Scale. b Tolvaptan Monitoring Policy. U&Es, Urea and Electrolytes. *Rapid correction of Na + is defined as rise in S/Na+ > target rise of 6 mmol/L over 12 h (and not exceeding 12 mmol/L over 1st 24 h) and an additional 8 mmol/L during every 24 h thereafter until the serum sodium concentration reaches 130 mmol/L.